Prostatype Genomics places 27,387,616 shares at SEK 0.10 in directed issue to Vator Securities, Tobias Wahlin

• Prostatype Genomics set a directed private placement of 3,423,452 units to Vator Securities, Tobias Wåhlin at SEK 0.8 per unit.
• Placement covers 27,387,616 new shares, issued with TO6, TO7 warrants; proceeds about SEK 2.7 million via set-off against existing claims.
• New shares imply about 4.9% dilution; dilution rises to about 8.3% if placement-linked TO6 and TO7 warrants are fully exercised.
• TO6 warrants exercisable Sept. 1-15 at SEK 0.1 per share; full exercise could raise about SEK 12.5 million before costs.
• TO7 warrants are Medicare-approval linked; exercise price 70% of VWAP, capped at SEK 0.2, floored at SEK 0.1; could raise about SEK 50.1 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prostatype Genomics AB published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.